Shareholder information Dividends per ADS Share price The table below sets out the dividends per ADS in US dollars in the 2006 2005 2004 last five years, translated into US dollars at applicable exchange rates.
The companys Dividend calendar share price decreased by 9% in 2006 from a price of 14.69 at 1st Fourth quarter 2006 January 2006 to 13.44 at 31st December 2006.
This compares with an increase in the FTSE 100 index of 11% during the year.
The share Ex-dividend date 14th February 2007 price on 23rd February 2007 was 14.50.
Record date 16th February 2007 Payable 12th April 2007 Market capitalisation The market capitalisation, based on shares in public issue, of First quarter 2007 GlaxoSmithKline at 31st December 2006 was 77 billion.
At that date Ex-dividend date 2nd May 2007 GSK was the fourth largest company by market capitalisation on the Record date 4th May 2007 FTSE index.
Payable 12th July 2007 SmithKline Beecham plc Floating Rate Unsecured Second quarter 2007 Loan Stock 1990 2010 Ex-dividend date 1st August 2007 The loan stock is not listed on any exchange but holders may require Record date 3rd August 2007 SmithKline Beecham plc to redeem their loan stock at par, i. e. 1 for Payable 11th October 2007 every 1 of loan stock held, on the first business day of March, June, September and December.
Holders wishing to redeem all or part of Third quarter 2007 their loan stock should complete the notice on the back of their loan Ex-dividend date 31st October 2007 stock certificate and return it to the registrar, to arrive at least 30 days Record date 2nd November 2007 before the relevant redemption date.
Payable 10th January 2008 Taxation Internet General information concerning the UK and US tax effects of share Information about the company including details of the share price is ownership is set out in 'Taxation information for shareholders' on available on GSKs website at www.
Information made available on the website does not constitute part of this Annual Report.
Dividends GlaxoSmithKline pays dividends quarterly.
Details of the dividends Investor relations declared, the amount and the payment dates are given in Note 14.
Investor Relations may be contacted as follows: Dividends per share UK The table below sets out the dividends per share in the last five years.
980 Great West Road, Brentford, Middlesex TW8 9GS Year pence Tel: 44 0 20 8047 5000 2006 48.0 USA 2005 44.0 One Franklin Plaza, PO Box 7929, Philadelphia PA 19101 2004 42.0 Tel: 1 888 825 5249 toll free 2003 41.0 Tel: 1 215 751 4000 outside the USA 2002 40.0 GSK Annual Report 2006 182 INVESTOR INFORMATION Shareholder information continued Analysis of shareholdings Number of % of total % of total Number of Analysis of shareholdings at 31st December 2006 accounts accounts shares shares Holding of shares Up to 1,000 130,906 71 1 46,807,426 1,001 to 5,000 41,712 23 2 89,668,014 5,001 to 100,000 10,210 5 2 148,081,033 100,001 to 1,000,000 1,048 1 6 366,110,174 Over 1,000,000 490 89 5,340,935,201 Totals 184,366 100 100 5,991,601,848 Held by Nominee companies 30,702 17 78 4,643,364,576 Investment and trust companies 57 1 58,018,488 Insurance companies 14 162,380 Individuals and other corporate bodies 153,591 83 5 324,318,199 BNY Nominees Limited 1 12 730,255,527 Held as Treasury shares by GlaxoSmithKline 1 4 235,482,678 Totals 184,366 100 100 5,991,601,848 The Bank of New Yorks holding held through BNY Nominees Limited represents the companys ADR programme, whereby each ADS represents two Ordinary Shares of 25p nominal value.
At 23rd February 2007, the number of holders of record of shares in the USA was 1,143 with holdings of 1,508,043 shares, and the number of registered holders of the ADRs was 39,173 with holdings of 423,258,574 ADRs.
Certain of these shares and ADRs were held by brokers or other nominees.
As a result the number of holders of record or registered holders in the USA is not representative of the number of beneficial holders or of the residence of beneficial holders.
Control of company As far as is known to the company, it is not directly or indirectly owned or controlled by one or more corporations or by any government.
The company does not know of any arrangements, the operation of which might result in a change in control of the company.
Major shareholders have the same voting rights per share as all other shareholders.
Substantial shareholdings At 23rd February 2007, the company had received notification of the following interests of 3% or more in the shares in issue, excluding Treasury shares: BNY Nominees Limited holds 846,517,149 shares representing 14.71%.
These shares are held on behalf of holders of ADRs, which evidence ADSs.
Legal & General Investment Management Limited holds 218,457,607 shares representing 3.80%.
Barclays PLC holds 240,119,101 shares representing 4.17%.
As far as is known to the company, no other person was the owner of 3% or more of the shares in issue, excluding Treasury Shares of the company.
Directors and Officers The interests of the Directors and Officers of the company in share options, as defined in the Companies Act 1985, of the company are given in the Remuneration Report pages 65 to 82.
Exchange controls and other limitations affecting security holders There are currently no UK laws, decrees or regulations restricting the import or export of capital or affecting the remittance of dividends or other payments to holders of the companys shares who are non-residents of the UK.
There are no limitations relating only to non-residents of the UK under English law or the companys Memorandum and Articles of Association on the right to be a holder of, and to vote in respect of, the companys shares.
Documents on display The Memorandum and Articles of Association of the company and other documents referred to in this Annual Report are available for inspection at the Registered Office of the company.
Publications In late March 2007 GSK will publish on the website its Corporate Responsibility Report covering performance in areas including community investment, ethics and integrity, access to medicines, R&D and environment health and safety.
GSK Annual Report 2006 183 INVESTOR INFORMATION Shareholder information continued Nature of trading market Annual General Meeting 2007 The Ordinary Shares of the company were listed on the London Stock The Queen Elizabeth II Conference Centre, 23rd May 2007 Exchange on 27th December 2000.
The shares were also listed on the Broad Sanctuary, Westminster, New York Stock Exchange NYSE in the form of American Depositary London SW1P 3EE Shares ADSs from the same date.
The Annual General Meeting is the company's principal forum for The following tables set out, for the periods indicated, the high and communication with private shareholders.
In addition to the formal low middle market closing quotations in pence for the shares on the business there will be a presentation by the Chief Executive Officer on London Stock Exchange, and the high and low last reported sales the performance of the Group and its future development.
There will prices in US dollars for the ADSs on the NYSE.
be opportunity for questions to the Board, and the Chairmen of the Board's committees will take questions on matters relating to those GlaxoSmithKline Pence per share committees.
High Low Investors holding shares in the company through a nominee service Quarter ended 31st March 2007 1493 1344 should arrange with that nominee service to be appointed as a February 2007 1493 1386 corporate representative or proxy in respect of their shareholding in January 2007 1418 1344 order to attend and vote at the meeting.
December 2006 1360 1326 ADR holders wishing to attend the meeting must obtain a proxy from November 2006 1427 1331 The Bank of New York which will enable them to attend and vote on October 2006 1511 1400 the business to be transacted.
ADR holders may instruct The Bank of September 2006 1499 1418 New York as to the way in which the shares represented by their ADRs Quarter ended 31st December 2006 1511 1326 should be voted by completing and returning the voting card provided Quarter ended 30th September 2006 1540 1418 by the bank in accordance with the instructions given.
Quarter ended 30th June 2006 1557 1455 Quarter ended 31st March 2006 1577 1424 Financial reporting Quarter ended 31st December 2005 1544 1395 Quarter ended 30th September 2005 1442 1308 Financial reporting calendar 2007 Quarter ended 30th June 2005 1377 1201 Announcement of 1st Quarter Results April 2007 Quarter ended 31st March 2005 1318 1175 Year ended 31st December 2004 1299 1042 Announcement of 2nd Quarter Results July 2007 Year ended 31st December 2003 1390 1000 Announcement of 3rd Quarter Results October 2007 Year ended 31st December 2002 1780 1057 Preliminary Announcement of Annual Results February 2008 Publication of Annual Report Review March 2008 US dollars per ADS High Low Results Announcements Quarter ended 31st March 2007 58.37 52.66 Results Announcements are issued to the London Stock Exchange February 2007 58.37 54.71 and are available on its news service.
Shortly afterwards, they are January 2007 55.95 52.66 issued to the media, are made available on the website and sent to December 2006 53.73 51.93 the US Securities and Exchange Commission and the NYSE.
November 2006 54.21 51.41 October 2006 56.20 53.21 Financial reports September 2006 56.76 53.23 The company publishes an Annual Report and, for the investor not Quarter ended 31st December 2006 56.20 51.41 needing the full detail of the Report, an Annual Review.
These are Quarter ended 30th September 2006 57.01 53.23 available from the date of publication on the website.
Quarter ended 30th June 2006 58.38 51.48 The Annual Review is sent to all shareholders.
Shareholders may also Quarter ended 31st March 2006 54.94 50.15 elect to receive the Annual Report by writing to the companys Quarter ended 31st December 2005 53.53 49.16 registrars.
Alternatively shareholders may elect to receive notification Quarter ended 30th September 2005 51.28 46.47 by email of the publication of financial reports by registering on Quarter ended 30th June 2005 51.40 45.19 www.
Quarter ended 31st March 2005 50.50 44.48 Year ended 31st December 2004 47.50 39.04 Copies of previous financial reports are available on the website.
Year ended 31st December 2003 47.40 32.75 Printed copies can be obtained from the registrar in the UK and from Year ended 31st December 2002 50.87 32.86 the GSK Response Center in the USA.
to 23rd February 2007 Queries relating to receipt of duplicate copies of GSKs publications should be addressed to the registrars.
GSK Annual Report 2006 184 INVESTOR INFORMATION Shareholder information continued Ordinary shares The companys shares are listed on the London Stock Exchange.
Registrar The companys registrars are: Lloyds TSB Registrars The Causeway, Worthing, West Sussex BN99 6DA www.
co. uk Tel: 0870 600 3991 inside the UK Tel: 44 0 121 415 7067 outside the UK The registrars also provide the following services: GlaxoSmithKline Investment Plan GlaxoSmithKline Individual Savings Account GlaxoSmithKline Corporate Sponsored Nominee Shareview service Shareview dealing service Dividend reinvestment plan Share dealing service Shareholders may buy or sell shares by internet or telephone through Shareview dealing, a share dealing service provided by Lloyds TSB Registrars.
For internet purchases and sales log on to www.
co. uk dealing and for telephone purchases and sales call 0870 850 0852 inside the UK only between 8.00am and 4.30pm, Monday to Friday.
Glaxo Wellcome and SmithKline Beecham corporate PEPs The Share Centre Limited Oxford House, Oxford Road, Aylesbury, Bucks HP21 8SZ Tel: 44 0 1296 414141 The provision of the details above is not intended to be an invitation or inducement to engage in an investment activity.
Advice on share dealing should be obtained from a stockbroker or independent financial adviser.
American Depositary Shares The companys shares are listed on the NYSE in the form of American Depositary Shares and these are evidenced by American Depositary Receipts ADRs, each one of which represents two Ordinary Shares.
In general, the NYSEs rules permit the company to follow UK corporate governance practices instead of those that apply in the USA, provided that the company explains any significant variations.
This explanation is provided on the companys website.
ADR programme administrator The ADR programme is administered by: The Bank of New York Shareholder Relations PO Box 11258, Church Street Station New York NY 10286-1258 www.
com Tel: 1 877 353 1154 toll free Tel: 1 212 815 3700 outside the USA The administrators also provide Global BuyDIRECT, a direct ADS purchase sale and dividend reinvestment plan for ADR holders.
GSK Response Center Tel: 1 888 825 5249 toll free GSK Annual Report 2006 185 INVESTOR INFORMATION
